OPK Earnings Prediction
The chart below shows how OPK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OPK sees a +1.50% change in stock price 10 days leading up to the earnings, and a +4.37% change 10 days following the report. On the earnings day itself, the stock moves by +1.15%. This data can give you a slight idea of what to expect for the next quarter's release.
OPK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
173.63M
-2.78%
-4.70%
Gross Margin
11.34%
-22.54%
-33.84%
Operating Margin
-61.78%
71.33%
82.51%
Net Margin
14.33%
130.30%
-353.18%
EPS
0.04
136.36%
-500.00%
No Data Available
OPK Earnings Analysis
Opko Health Inc. Corporation (OPK.O) Earnings Conference Call
Positive
Q3 Revenue Comparison: Revenue for the third quarter of 2024 was $121.3 million, compared to $131.7 million for the 2023 period, indicating strong performance despite a decrease.
Operating Income Improvement: Operating income for the third quarter of 2024 was $58.5 million, compared to an operating loss of $29.1 million for the 2023 quarter, showcasing significant improvement.
Net Income Turnaround: Net income for the third quarter of 2024 was $24.9 million, or $0.03 per diluted share, compared to a net loss of $84.5 million, or $0.11 per share for the 2023 period, reflecting a strong turnaround.
Diagnostic Segment Resilience: The diagnostic segment's revenue was $121.3 million for the third quarter of 2024, demonstrating resilience in the face of market challenges.
Pharmaceutical Revenue Growth: The pharmaceutical segment's revenue increased to $52.4 million for the third quarter of 2024, compared to $46.9 million for the comparable period of 2023, indicating growth in product sales.
Negative
Revenue Decline Analysis: Revenue decreased to $121.3 million for Q3 2024, down from $131.7 million in Q3 2023, primarily due to lower testing volumes.
Rising Operational Costs: Costs and expenses totaled $184.2 million in Q3 2024, compared to $160.8 million for the same period in 2023, indicating rising operational costs.
Worsening Operating Loss: Operating loss for Q3 2024 was $32.2 million, compared to an operating loss of $25.4 million for Q3 2023, reflecting worsening financial performance.
Net Income Fluctuation: Net income for Q3 2024 was $24.9 million, a significant drop from a net loss of $84.5 million in Q3 2023, highlighting volatility in earnings.
Diagnostic Segment Expenses: Depreciation and amortization expense for the diagnostic segment increased to $6.1 million in Q3 2024 from $8.4 million in Q3 2023, indicating higher asset-related costs.
OPK FAQs
How does OPK typically perform around its earnings report dates?
Is OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OPK Earning Call Sentiment
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript
1.0x
00:00
00:00
OPK.O
0%Positive
The earnings call summary presents a mixed but overall positive outlook. Financial performance shows a strong net income turnaround and improved profitability from Pfizer, despite some revenue declines. The share repurchase program positively impacts shareholder return. The Q&A reveals a lack of clarity on some product developments but overall positive sentiment towards ongoing projects. The collaboration with Merck and cost reduction initiatives add positive momentum. Considering these factors, the stock price is likely to see a positive movement in the next two weeks.
